By Marie Rosenthal, MS
SAN ANTONIO—Patients with transfusion-dependent beta thalassemia (beta thal) have a high disease burden that requires specialized care. Although there are curative therapies for the disease, they are expensive, and may not be available for all patients. But then, they might not be appropriate for all patients either, explained Jennifer Billings, PharmD, BCGP, director of clinical pharmacy at IPD Analytics, a syndicated healthcare and drug intelligence consulting